Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of the Use of Regional Anticoagulation With Citrate in Continuous Venovenous Hemofiltration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intensive care patients scheduled for continuous venovenous hemofiltration~Exclusion Criteria:~* Severe pre-existent liver failure (cirrhosis Child C), acute liver dysfunction as occurring with septic shock is not a reason for exclusion~* Active bleeding or bleeding necessitating the infusion of two red blood cell units within 24 hours before starting hemofiltration or a fall in hemoglobin of \> 0.5 mmol/l. A fall in hemoglobin/hematocrit as a result of fluid loading is not regarded as bleeding.~* Surgery within 24 h prior to CVVH.~* Patients needing full systemic anticoagulation (unfractionated heparin in a dose of \> 10000 IU/day, or nadroparin \> 3800 IU/day) for other reasons~* Expectation to die within 24 hours~* Chronic dialysis~* Proven or suspected heparin-induced thrombocytopenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- citrate (Type: ACTIVE_COMPARATOR): regional anticoagulation with citrate
- nadroparin (Type: ACTIVE_COMPARATOR): nadroparin is a low molecular weight heparin

Based on this trial design, predict the completion outcome and termination type (if applicable).